1Iakovou I,Schmidt T,Bonizzoni E,et al.Incidence,predictors,and outcome of thrombosis after successful implantation of drug-eluting stents.JAMA,2005,293:2126-2130.
3Nguyen TA,Diodati JG,Pharand C.Resistance to clopidogrel:a review of the evidence.J Am Coll Cardiol,2005,45:1157-1164.
4Lau WC,Gurbel PA,Watkins PB,et al.Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.Circulation,2004,109:166-171.
5Mobley JE,Bresee SJ,Wortham DC,et al.Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization.Am J Cardiol,2004,93:456-458.
6Lepantalo A,Virtanen KS,Heikkila J,et al.Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.Eur Heart J,2004,25:476-483.
7Matetzky S,Shenkman B,Guetta V,et al.Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.Circulation,2004,109:3171-3175.
8Muller I,Besta F,Schulz C,et al.Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement.Thromb Haemost,2003,89:783-787.
9Lev EI,Patel RT,Maresh KJ,et al.Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance.J Am Coll Cardiol,2006,47:27-33.
10Serebruany VL,Steinhubl SR,Berger PB,et al.Variability in platelet responsiveness to clopidogrel among 544 individuals.J Am Coll Cardiol,2005,45:246-251.
二级参考文献2
1Lemos PA, Saia F, Hofma SH, et al. Short-term and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol, 2004, 43:704-708.
2Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation, 2004,109:701-705.
